Clearmind Medicine Secures European Patent for Cocaine Addiction Therapy
Ticker: CMND · Form: 6-K · Filed: May 12, 2025 · CIK: 1892500
| Field | Detail |
|---|---|
| Company | Clearmind Medicine INC. (CMND) |
| Form Type | 6-K |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: patent, pharmaceuticals, drug-development, addiction-treatment
TL;DR
Clearmind got a European patent for a cocaine addiction drug combo. Big win for their IP.
AI Summary
Clearmind Medicine Inc. announced on May 12, 2025, that it has been granted a European Patent for its psychedelic-based combination therapy aimed at treating cocaine addiction. This patent covers the use of MEAI (5-methoxy-2-aminoindoline) in combination with other therapeutic agents for the treatment of cocaine use disorder.
Why It Matters
This patent strengthens Clearmind's intellectual property portfolio and could pave the way for future clinical trials and commercialization of a novel treatment for cocaine addiction.
Risk Assessment
Risk Level: medium — The company is still in the early stages of development, and the success of the therapy in clinical trials and market adoption is not guaranteed.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Filer of the 6-K and developer of the patented therapy.
- May 12, 2025 (date) — Date of the press release announcing the patent.
- European Patent (patent) — The intellectual property granted to Clearmind Medicine.
- MEAI (5-methoxy-2-aminoindoline) (drug) — The psychedelic compound central to the patented therapy.
- cocaine addiction (medical_condition) — The condition the therapy is designed to treat.
FAQ
What is the specific therapeutic agent mentioned in the patent filing?
The press release mentions MEAI (5-methoxy-2-aminoindoline) in combination with other therapeutic agents.
What is the primary indication for the patented therapy?
The therapy is for the treatment of cocaine addiction, specifically cocaine use disorder.
On what date was the press release announcing this patent issued?
The press release was issued on May 12, 2025.
Which regulatory body granted the European Patent?
The filing indicates a European Patent was granted, but does not specify the exact European patent office.
What is Clearmind Medicine Inc.'s principal executive office location?
Clearmind Medicine Inc.'s principal executive offices are located at 101 – 1220 West 6th Avenue, Vancouver, British Columbia.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 12, 2025 regarding Clearmind Medicine Inc. (CMND).